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HSV‑2 as a biomarker of HIV 
epidemic potential in female sex 
workers: meta‑analysis, global 
epidemiology and implications
Hiam Chemaitelly1,2,3*, Helen A. Weiss4 & Laith J. Abu‑Raddad1,2,5
This study investigated herpes simplex virus type 2 (HSV‑2) seroprevalence utility as a predictor 
of HIV epidemic potential among female sex workers (FSWs) globally. We updated and analyzed a 
systematically‑assembled database for paired HSV‑2 and HIV seroprevalence measures among FSWs. 
The study identified 231 paired HSV‑2/HIV prevalence measures from 40 countries. The pooled mean 
HIV prevalence using meta‑analysis increased from 3.7% (95% CI 0.3–9.9%) among populations 
of FSWs with HSV‑2 prevalence < 25% to 18.7% (95% CI 14.1–23.8%) among those with HSV‑2 
prevalence 75–100%. HIV prevalence was negligible in FSWs with HSV‑2 prevalence ≤ 20% suggesting 
a threshold effect. Multivariable meta‑regressions explained > 65% of HIV prevalence variation, and 
identified a strong positive HSV‑2/HIV association. Compared to populations of FSWs with HSV‑2 
prevalence < 25%, adjusted odds ratios (AORs) of HIV infection increased from 2.8 (95% CI 1.2–6.3) 
in those with HSV‑2 prevalence 25–49%, to 13.4 (95% CI 6.1–29.9) in those with HSV‑2 prevalence 
75–100%. HSV‑2 is a strong predictor of HIV epidemic potential among FSWs. HSV‑2 prevalence of 
25–49% indicates potential for intermediate‑intensity HIV epidemics, with higher levels indicative of 
large epidemics. HSV‑2 surveillance could inform HIV preparedness in countries where HIV prevalence 
among FSWs is still limited or at zero‑level.
Female sex workers (FSWs) continue to be a vulnerable and stigmatized population that is disproportionately 
affected by  HIV1–3. Although FSWs generally constitute a small proportion of the total adult female population, 
typically less than 1%, this translates to millions of women globally that are at high risk of HIV infection and in 
need of prevention or treatment  services4,5.
In resource-limited settings, HIV prevalence among FSWs is estimated at an average of 12%, with odds of 
infection being 14-fold higher than among women in the general  population2. Despite their increased risk, 
access to testing and linkage to treatment is often suboptimal, and could be even lower than that of women in 
the general  population6. Until recently, HIV prevalence among FSWs in the World Health Organization (WHO) 
Eastern Mediterranean Region (EMRO) has been persistently very  low2, with the exception of Djibouti and South 
Sudan where the epidemic is established at ~ 20%5,7. Over the last decade, however, epidemics emerged in this 
population in a number of EMRO  countries5. While HIV prevalence remains low, it has been growing rapidly, 
by as much as ~ 15% per  year5, with the potential for further growth being unknown. Epidemic potential is also 
unknown for half of EMRO countries where studies have consistently assessed HIV prevalence among FSWs at 
zero or negligible levels, but where documented overlap with other at-risk populations may create opportunities 
for seeding  epidemics5.
Predicting HIV epidemic potential, that is the level that HIV prevalence can reach in a population, is essential 
for informing program development and resource  allocation8. One approach is to use self-reported sexual risk 
behavior data. The latter, however, is limited by reporting bias, recall bias, limitations in value of ego-centric data 
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to map level of risk in the sexual network, poor representability due to insufficient integrated bio-behavioral 
surveillance surveys (IBBSS), and lack of standardization across  studies5,9–12. Since herpes simplex virus type 2 
(HSV-2) is almost exclusively sexually transmitted, is more transmissible than HIV, and produces long-lasting 
antibodies, it has been used as a biological marker of sexual risk and objective indicator of the risk of exposure to 
 HIV8,9,13–15. It is also believed, based on observational evidence, that there is an epidemiologic synergy between 
HSV-2 and HIV  infection16–18, though recent evidence has casted doubt about this  synergy19. Earlier analyses 
using empirical data as well as mathematical modeling also supported the utility of HSV-2 in predicting HIV 
epidemic  potential8,9,20.
Limited HIV prevalence is often observed among FSWs in various settings suggesting that the virus may not 
yet have been introduced in commercial heterosexual sex networks, or may not have had sustainable transmis-
sion upon  introduction2,5. In situations where HIV prevalence has been repeatedly assessed at zero or negligible 
levels, such as for several EMRO countries, periodic IBBSS for HIV surveillance, though desirable, is often (incor-
rectly) perceived as  unnecessary21–23. Testing for other sexually transmitted infections (STIs) such as HSV-2 are 
also typically not incorporated in HIV surveillance  activities21,22,24. However, the recent emergence and steady 
growth of HIV epidemics among FSWs in different EMRO countries, after years of limited or no prevalence, 
advocate for the relevance and urgency of collecting such data to enable assessment of HIV epidemic potential 
in these  settings5.
This study systematically reviews paired HSV-2 and HIV (antibody) prevalence data among FSWs, globally, 
and analyzes these data to investigate use and utility of HSV-2 as a predictor of HIV prevalence and epidemic 
potential among FSWs by (1) estimating the pooled mean HIV prevalence at various HSV-2 prevalence levels, 
and (2) determining the magnitude of the HSV-2/HIV ecological association in light of regional, temporal, and 
condom use differences among FSWs.
Results
Search results and scope. The systematic search identified a total of 3386 citations, which after remov-
ing duplicates and screening, yielded 78 eligible reports (Fig. 1). Hand searching of the reference lists of eligible 
reports and reviews yielded three additional articles, and one comprehensive country-level public health report 
from  India25 that replaced three other full-texts26–28. Two reports were further excluded after consulting with 
Professor Rhoda Ashley-Morrow, an expert advisor in HSV-2 diagnostics, because the reliability of HSV-2 sero-
logic testing could not be  confirmed29,30. In total, 77 reports comprising 231 paired HSV-2 and HIV prevalence 
measures among FSWs, from 40 countries, were eligible for inclusion. These contributed to the database gener-
ated through our earlier systematic  review20 a total of 63 additional paired HSV-2 and HIV prevalence measures 
from 17 recent reports. Identified measures dated from 1988–2018 and are tabulated in Table S1 of Supplemen-
tary Information (SI) based on WHO regional classification [Region of the Americas (AMRO), African Region 
(AFRO), EMRO, European Region (EURO), South-East Asia Region (SEARO), and Western Pacific Region 
(WPRO)].
As the focus of this work is on examining the association between the two infections, it was pre-decided 
to restrict the analysis to settings where HIV has been introduced; we therefore excluded 37 paired measures 
with zero HIV prevalence from further analysis. After excluding measures with zero HIV prevalence, analysis 
was performed on a total of 194 paired measures from 33 countries (Fig. S1 of SI). India contributed the largest 
number of measures (n = 58; 29.9%), followed by China (n = 37, 19.1%), then Peru (n = 19; 9.8%). The distribu-
tion of measures across world regions is illustrated in Fig. 2A,B. The highest data contribution was for SEARO 
(n = 71; 36.6%), followed by AFRO and AMRO (each with n = 41; 21.1%), WPRO (n = 38; 19.6%), and lastly 
EURO (n = 3; 1.6%). There were only four studies from EMRO, all of which reported zero HIV prevalence, and 
thus were excluded from analysis.
Overview of the distribution of HIV prevalence by HSV‑2 prevalence. Table 1 summarizes HIV 
prevalence data among FSWs, stratified by HSV-2 prevalence. Globally, among FSWs with HSV-2 preva-
lence < 25%, the median HIV prevalence was 2.0% (n = 8; range = 0.1–32.7%), increased slightly to 2.5% (n = 23; 
range = 0.2–33.3%) with HSV-2 prevalence 25–49%, then increased sharply to 10.8% (n = 92; range = 0.2–39.7%) 
with HSV-2 prevalence 50–74%, and to 14.9% (n = 71; range = 0.2–76.8%) with HSV-2 prevalence 75–100%. 
The scatterplots illustrating the distribution of the paired HSV-2 and HIV prevalence measures further sug-
gested a threshold effect with limited HIV prevalence at HSV-2 prevalence ≤ 20% (Fig. 2A; n = 13; median = 0.0; 
range = 0.0–2.0).
In AFRO, HSV-2 prevalence among FSWs was > 50% in almost all studies. The median HIV prevalence was 
20.0% (n = 21; range = 6.6–39.7%) with HSV-2 prevalence 50–74%, and 50.0% (n = 18; range = 11.8–76.8%) with 
HSV-2 prevalence 75–100%. In the other regions, the median HIV prevalence was 2.0% (n = 7; range = 0.1–5.3%) 
with HSV-2 prevalence < 25%, 2.5% (n = 22; range = 0.2–27.4%) with HSV-2 prevalence 25–49%, 7.7% (n = 71; 
range = 0.2–27.4%) with HSV-2 prevalence 50–74%, and 9.5% (n = 53; range = 0.2–47.1%) with HSV-2 prevalence 
75–100%.
The median proportion of FSWs who inject drugs was 3.3% (n = 33; range = 0.0–81.9; Table S1 of SI). It 
was 1.2% (n = 11; range = 0.5–51.6%) in AMRO, 3.5% (n = 10; range = 0.0–3.9%) in SEARO, and 7.4% (n = 9; 
range = 1.3–81.9%) in WPRO. Meanwhile, there were no studies from AFRO, only one study from EURO report-
ing this proportion at 0%, and two studies from EMRO each reporting this proportion at 3.0%.
The median HSV-2 prevalence across these studies was assessed at 33.3% (range = 4.7–95.7) while the median 
HIV prevalence was assessed at 3.2% (range = 0.0–39.1%). In studies where the proportion of FSWs who inject 
drugs was < 5%, the median HSV-2 prevalence was 30.0% (range = 4.7–95.7%) while the median HIV preva-
lence was 2.0% (n = 19; 95% CI 0.0–9.6%). In studies where the proportion of FSWs who inject drugs was ≥ 5% 
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but < 10%, the median HSV-2 prevalence was 70.8% (n = 7; range = 29.7–86.6%) while the median HIV preva-
lence was 5.2% (95% CI 0.0–39.1%). In studies where the proportion of FSWs who inject drugs was ≥ 10%, the 
median HSV-2 prevalence was 82.0% (n = 3; range = 72.9–92.6%) while the median HIV prevalence was 4.1% 
(95% CI 0.3–38.3%).
Pooled mean HIV prevalence stratified by HSV‑2 prevalence. The results of meta-analyses estimat-
ing the pooled mean HIV prevalence stratified by HSV-2 prevalence are presented in Table 1. Forest plots are 
shown in Fig. S2 of SI.
Across world regions, the pooled mean HIV prevalence was estimated at 3.7% (95% confidence interval 
(CI) = 0.3–9.9%) with HSV-2 prevalence < 25%, 4.5% (95% CI 2.0–7.9%) with HSV-2 prevalence 25–49%, 10.1% 
(95% CI 8.2–12.3%) with HSV-2 prevalence 50–74%, and 18.7% (95% CI 14.1–23.8%) with HSV-2 prevalence 
75–100%.
Estimates in AFRO were higher at 22.2% (95% CI 17.6–27.1%) with HSV-2 prevalence 50–74%, and 47.7% 
(95% CI 39.4–55.9%) with HSV-2 prevalence 75–100%. In the rest of world regions, the pooled mean HIV 
prevalence was 1.7% (95% CI 0.3–3.8%) with HSV-2 prevalence < 25%, 3.9% (95% CI 1.6–7.1%) with HSV-2 
Figure 1.  Flow chart presenting the process of study selection following PRISMA  guidelines47.
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prevalence 25–49%, 7.5% (95% CI 5.9–9.2%) with HSV-2 prevalence 50–74%, and 11.3% (95% CI 8.0–15.2%) 
with HSV-2 prevalence 75–100%.
There was evidence for heterogeneity in HIV prevalence in all meta-analyses: Cochran’s Q statistic p values 
were < 0.01,  I2 was mostly > 90% indicating that most variability is due to true differences in HIV prevalence 
rather than chance, and prediction intervals were generally wide affirming heterogeneity.
Association of HSV‑2 with HIV prevalence. Table  2 shows the results of meta-regression analyses 
examining the association between HIV prevalence and HSV-2 prevalence among FSWs globally. In the uni-
variable analyses, HSV-2 prevalence, WHO region, year of data collection, and proportion of FSWs reporting 
consistent condom use were associated with HIV prevalence at p value ≤ 0.2, and hence were included in the 
multivariable analysis.
The multivariable models, whether considering HSV-2 prevalence as a categorical variable (Model 1) or as 
a linear variable (Model 2), both showed strong evidence for an association with HSV-2 and WHO region (p 
value ≤ 0.05). Some evidence for an association, that is a p value between 0.05 and 0.1, was found for consistent 
condom use, but no evidence (p value > 0.1) was found for year of data collection. Models 1 and 2 explained, 
respectively, 65.3% and 70.6% of the variation in HIV prevalence.
Model 1 showed that, relative to FSWs with HSV-2 prevalence < 25%, odds of HIV infection were three-fold 
higher (95% CI 1.2–6.3) among those with HSV-2 prevalence 25–49%, five-fold higher (95% CI 2.4–11.3) among 
those with HSV-2 prevalence 50–74%, and 13-fold higher (95% CI 6.1–29.9) among those with HSV-2 prevalence 
75–100%. Regional differences were identified, where compared to AMRO, odds were four-fold higher for EURO 
(95% CI 1.0–12.1), six-fold higher for WPRO (95% CI 3.4–9.9), 11-fold higher for SEARO (95% CI 7.0–17.8), and 
thirty-seven-fold higher for AFRO (95% CI 23.2–59.4). FSWs reporting 25–49% consistent condom use had twice 
higher odds of HIV infection compared to those reporting 75–100% consistent condom use (95% CI 1.0–3.2).
Similar results were found using Model 2. Here, however, a 1% increase in HSV-2 prevalence among FSWs, 
beyond the 20% threshold, was associated with a 4% increase in the odds of HIV infection (adjusted odds ratio 
(AOR) = 1.04, 95% CI 1.03–1.05).
Figure 2.  Scatterplot showing the global distribution of the paired herpes simplex type 2 (HSV-2) and HIV 
prevalence measures among female sex workers. (A) Distribution of all measures identified through the 




Scientific Reports |        (2020) 10:19293  | https://doi.org/10.1038/s41598-020-76380-z
www.nature.com/scientificreports/
Table 3 shows the results of meta-regression analyses excluding AFRO. Results were consistent with those 
for all regions (Table 2). In Model 1, relative to FSWs with HSV-2 prevalence < 25%, AORs were 4.0 (95% CI 
1.7–9.8), 7.8 (95% CI 3.3–18.2), 19.1 (95% CI 7.9–46.1) among those with HSV-2 prevalence 25–49%, 50–74%, 
and 75–100%, respectively. The AOR in the linear association (Model 2) was 1.04 (95% CI 1.03–1.05).
Discussion
Motivated by the concept of using current HSV-2 prevalence in a population as a proxy biomarker of future HIV 
prevalence in that  population8,9,20 and its relevance to HIV preparedness, this study assessed the utility of HSV-2 
as a predictor of HIV epidemic potential among FSWs through a global systematic analysis of empirical paired 
HSV-2 and HIV prevalence measures. We found strong evidence for an association between HIV and HSV-2 
prevalence, even after accounting for potential confounders such as region, temporal trend, and condom use 
(Tables 2 and 3). HIV prevalence was negligible at HSV-2 prevalence ≤ 20% (Fig. 2), but increased steadily with 
higher HSV-2 prevalence suggesting a threshold effect—the odds of HIV infection doubled with a 25% increase 
in HSV-2 prevalence (Tables 1 and 2). These findings demonstrate that in populations where HIV prevalence 
is still limited, but has potential to grow, HSV-2 prevalence can be used to provide a prediction of future HIV 
prevalence.
The hierarchy of HIV prevalence among FSWs was evident even in the context of Africa’s general population 
HIV epidemics (Table 1). Outside the African Region, HSV-2 prevalence among FSWs of 25–49% was indica-
tive of the potential for intermediate-intensity HIV epidemics with an HIV prevalence of ~ 5% or less. For FSW 
populations with HSV-2 prevalence ≥ 50%, HIV prevalence was higher and often exceeded 10%. Our findings 
based on analysis of empirical data substantiate mathematical modeling analyses predicting quantitatively such 
an  association8,9, which also appears to exist for other  populations20. The modeling analyses simulating HSV-2 
and HIV propagation along diverse sexual networks demonstrated that HSV-2 prevalence ≥ 50% is indicative 
of substantial sexual risk behavior, sufficient to sustain large HIV epidemics in a sexual  network9. In contrast, 
HSV-2 prevalence < 20% in a sexual network is indicative of low sexual risk behavior that is not likely to sustain 
an epidemic (a “threshold effect”)8. Both of these modeling predictions were confirmed in the present study 
through analysis of actual empirical data (Table 1).
After decades of virtually zero HIV  prevalence2, EMRO has recently seen emergence of HIV epidemics 
among FSWs in several  countries5. However, and despite an apparently rapid epidemic growth, HIV prevalence 
in FSWs remains overall at low  levels5. It is unfortunate that there were too few HSV-2 prevalence measures 
among FSWs in this region to predict HIV epidemic potential (Table S1 of SI)24. Available measures indicated 
also relatively low HSV-2 prevalence, often below 20% (Table S1 of SI)24, the apparent threshold for a significant 
Table 1.  Results of meta-analyses on studies reporting HIV prevalence among female sex workers stratified 
by HSV-2 prevalence levels. CI, confidence interval; HSV-2, herpes simplex virus type 2. a Excluding 37 studies 
with zero HIV prevalence. b Meta-analysis not possible for a single study. c Q: the Cochran’s Q statistic is a 
measure assessing the existence of heterogeneity in effect size (here, HIV prevalence) across studies. d I2: a 
measure assessing the magnitude of between-study variation that is due to differences in effect size (here, HIV 
prevalence) across studies rather than chance. e Prediction interval: a measure estimating the 95% interval of 
the distribution of true effect sizes (here, HIV prevalence).
HSV-2  prevalencea
Studies Samples HIV prevalence
Pooled mean HIV 
prevalence Heterogeneity measures
N Tested HIV positive Median (%) Range (%) (%) 95% CI Q (p value)c I2d (%; 95% CI)
Prediction  intervale 
(95%)
African region
 < 25% 1b 220 72 32.7 – – – – – –
 25–49% 1b 54 18 33.3 – – – – – –
 50–74% 21 6895 1711 20.0 6.6–39.7 22.2 17.6–27.1 418.7 (p < 0.01) 95.2 (93.8–96.3) 4.5–47.6
 75–100% 18 5829 2670 50.0 11.8–76.8 47.7 39.4–55.9 614.1 (p < 0.01) 97.2 (96.5–97.8) 14.1–82.5
 Total 41 12,998 4471 32.7 6.6–76.8 33.1 27.8–38.7 1696.8 (p < 0.01) 97.6 (97.3–98.0) 5.2–70.0
Other WHO regions
 < 25% 7 2190 35 2.0 0.1–5.3 1.7 0.3–3.8 47.9 (p < 0.01) 87.5 (76.5–93.3) 0.0–12.0
 25–49% 22 8280 580 2.5 0.2–27.4 3.9 1.6–7.1 877.1 (p < 0.01) 97.6 (97.1–98.1) 0.0–27.8
 50–74% 71 28,935 2521 7.7 0.2–27.4 7.5 5.9–9.2 1954.2 (p < 0.01) 96.4 (95.9–96.9) 0.0–26.3
 75–100% 53 15,243 2222 9.5 0.2–47.1 11.3 8.0–15.2 2607.0 (p < 0.01) 98.0 (97.7–98.2) 0.0–48.1
 Total 153 54,648 5358 5.9 0.1–47.1 7.8 6.4–9.3 6130.8 (p < 0. 01) 97.5 (97.3–97.7) 0.0–33.2
Global
 < 25% 8 2410 107 2.0 0.1–32.7 3.7 0.3–9.9 247.7 (p < 0.01) 97.2 (95.9–98.1) 0.0–37.2
 25–49% 23 8334 598 2.5 0.2–33.3 4.5 2.0–7.9 911.0 (p < 0.01) 97.6 (97.0–98.0) 0.0–29.6
 50–74% 92 35,830 4232 10.8 0.2–39.7 10.1 8.2–12.3 3633.0 (p < 0.01) 97.5 (97.2–97.7) 0.0–36.0
 75–100% 71 21,072 4892 14.9 0.2–76.8 18.7 14.1–23.8 5844.9 (p < 0.01) 98.8 (98.7–98.9) 0.0–69.2
 Total 194 67,646 9829 10.1 0.1–76.8 11.8 9.9–13.9 12,598.5 (p < 0.01) 98.5 (98.4–98.6) 0.0–49.3
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HIV epidemic (Fig. 2). HSV-2 prevalence in the general population in EMRO also appears to be low, and overall 
lower than that in other  regions8,31. Indeed, a recent global  assessment32 estimated HSV-2 prevalence among 
women in the general population at 7.6% in EMRO, 9.6% in SEARO, 10.7% in EURO, 14.6% in WPRO, 24.0% 
in AMRO, and 43.9% in AFRO, whereas median HSV-2 prevalence among FSWs in our study was > 50% in all 
regions aside from EMRO. This suggests that HIV prevalence may not grow to reach considerable levels in many 
FSW populations in EMRO, and possibly will persist at levels close to zero HIV prevalence. Having said so, this 
region could largely benefit from integrating testing for HSV-2 in HIV surveillance activities. However, much 
more data on HSV-2 prevalence are needed before we can assess HIV epidemic potential among FSWs in this 
region with meaningful confidence.
Table 2.  Results of meta-regression analyses assessing the association between HIV prevalence and HSV-2 
prevalence among female sex workers globally. Adj, Adjusted; AFRO, African Region; AMRO, Region of the 
Americas; AOR, adjusted odds ratio; CI, confidence interval; EURO, European Region; FSWs, female sex 
workers; HSV-2, herpes simplex virus type 2; OR, odds ratio; SEARO, South-East Asia Region; WHO, World 
Health Organization; WPRO, Western Pacific Region. Adjusted  R2 is 65.3% in the multivariable model 1, and 
70.6% in the multivariable model 2. a Factors with p value ≤ 0.2 were eligible for inclusion in the multivariable 
analysis. b Factors with p value ≤ 0.05 and those with 0.05 < p value ≤ 0.1 in the multivariable model were 
considered as showing, respectively, “strong” and “some” evidence for an association with HIV prevalence. 
c Analysis of the association with HSV-2 prevalence as a linear term excluded three measures with HSV-2 
prevalence ≤ 20% in light of the observed threshold effect. d Missing values for year of data collection were 
imputed using data for year of publication adjusted by the median difference between year of publication and 
median year of data collection for studies with complete information.
Factors
Studies Samples Univariable analyses Multivariable analysis-model 1 Multivariable analysis-model 2
Total n Total n OR (95% CI) p value F p  valuea Adj.  R2 (%) AOR (95% CI) p value F p  valueb AORc (95% CI) p value F p  valueb
HSV-2 prevalence
 < 25% 8 2410 1.0  < 0.01 10.8 1.0  < 0.01 – – –
 25–49% 23 8334 1.4 (0.4–5.0) 0.60 2.8 (1.2–6.3) 0.01 – – –
 50– 74% 92 35,830 4.0 (1.3–12.6) 0.02 5.2 (2.4–11.3)  < 0.01 – – –
 75–100% 71 21,072 7.2 (2.3–22.7)  < 0.01 13.4 (6.1–29.9)  < 0.01 – – –
HSV-2 prevalencec
191 66,239 1.03 (1.02–1.04)  < 0.01  < 0.01 10.8 – – – 1.04 (1.03–1.05)  < 0.01  < 0.01
WHO region
 AMRO 41 12,037 1.0  < 0.01 48.5 1.0  < 0.01 1.0  < 0.01
 AFRO 41 12,998 31.7 (19.0–53.0)  < 0.01 37.1 (23.2–59.4)  < 0.01 36.2 (23.6–55.7)  < 0.01
 EURO 3 718 1.3 (0.3–5.2) 0.70 3.5 (1.0–12.1) 0.05 5.5 (1.7–17.5)  < 0.01
 SEARO 71 24,047 8.5 (5.4–13.4)  < 0.01 11.2 (7.0–17.8)  < 0.01 12.5 (8.1–19.1)  < 0.01
 WPRO 38 17,846 3.8 (2.3–6.4)  < 0.01 5.8 (3.4–9.9)  < 0.01 6.2 (3.8–10.0)  < 0.01
Publication year
 < 2000 15 5049 1.0 0.83 0.0 – – – – – –
 2000–2004 7 2368 1.2 (0.3–5.5) 0.80 – – – – – –
 2005–2009 56 13,855 1.7 (0.6–4.3) 0.30 – – – – – –
 2010–2014 99 40,760 1.4 (0.6–3.6) 0.44 – – – – – –
 2015– 2019 17 5614 1.2 (0.4–3.7) 0.81 – – – – – –
Data collection  yeard
 < 1995 18 6478 1.0 0.11 1.8 1.0 0.15 1.0 0.17
 1995–1999 14 2462 1.0 (0.3–3.1) 0.97 0.7 (0.3–1.5) 0.31 0.7 (0.3–1.3) 0.26
 2000–2004 61 15,736 1.0 (0.4–2.5) 0.93 1.0 (0.6–1.7) 0.98 1.0 (0.6–1.6) 0.85
 2005–2009 88 37,770 2.0 (0.9–4.6) 0.10 1.4 (0.8–2.5) 0.30 1.3 (0.8–2.3) 0.34
 2010–2014 13 5200 1.4 (0.4–4.6) 0.56 0.6 (0.3–1.3) 0.19 0.6 (0.3–1.3) 0.22
Sample size
 < 200 52 5507 1.0 0.76 0.0 – – – – – –
 ≥ 200 142 62,139 0.92 (0.54–1.56) 0.76 – – – – – –
Proportion of FSWs reporting consistent condom use
 75–100% 77 31,462 1.0 0.09 2.1 1.0 0.09 1.0 0.08
 50–74% 19 8129 0.4 (0.2–1.0) 0.04 1.1 (0.6–1.9) 0.79 1.2 (0.7–2.0) 0.55
 25–49% 31 6367 1.4 (0.7–2.7) 0.38 1.8 (1.0–3.2) 0.05 1.9 (1.1–3.2) 0.02
 < 25% 9 3715 1.1 (0.3–3.3) 0.91 0.7 (0.3–1.5) 0.31 0.8 (0.4–1.6) 0.51
 Unclear 58 17,973 0.7 (0.4–1.2) 0.19 1.3 (0.8–2.1) 0.30 1.2 (0.8–1.8) 0.47
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Several other findings emerged from this study. There was regional variation in HIV prevalence that could not 
be captured by HSV-2 prevalence, especially so for the African Region (Table 2), but also outside Africa (Table 3). 
This finding suggests that other factors may differentially impact each of HSV-2 and HIV prevalence, and that 
these should be accounted for to better describe the HIV/HSV-2 association. This is also supported by modeling 
analyses that demonstrated that, while some sexual network statistics affect HSV-2 and HIV transmission simi-
larly, others can affect them  differentially9. A plausible explanation relates to HIV having lower infectiousness and 
shorter acute infection duration, therefore facing more difficulty in propagating within sexual networks compared 
to HSV-29. For instance, while concurrency (mean number of current sexual partners) is a strong predictor of 
both HSV-2 and HIV prevalence, clustering within a sexual network (or high exposure within specific circles), 
provides a higher chance for HIV to spread, but limits HSV-2 from reaching farther nodes in the wider sexual 
Table 3.  Results of meta-regression analyses assessing the association between HIV prevalence and HSV-2 
prevalence among female sex workers globally but excluding the African Region. Adj, Adjusted; AMRO, 
Region of the Americas; AOR, adjusted odds ratio; CI, confidence interval; EURO, European Region; FSWs, 
female sex workers; HSV-2, herpes simplex virus type 2; OR, odds ratio; SEARO, South-East Asia Region; 
WHO, World Health Organization; WPRO, Western Pacific Region. Adjusted  R2 is 58.2% in the multivariable 
model 1, and 64.1% in the multivariable model 2. a Factors with p value ≤ 0.2 were eligible for inclusion in 
the multivariable analysis. b Factors with p value ≤ 0.05 and those with 0.05 < p value ≤ 0.1 in the multivariable 
model were considered as showing, respectively, “strong” and “some” evidence for an association with HIV 
prevalence. c Analysis of the association with HSV-2 prevalence as a linear term excluded three measures with 
HSV-2 prevalence ≤ 20% in light of the observed threshold effect. d Missing values for year of data collection 
were imputed using data for year of publication adjusted by the median difference between year of publication 
and median year of data collection for studies with complete information.
Factors
Studies Samples Univariable analyses Multivariable analysis-model 1 Multivariable analysis-model 2




 < 25% 7 2190 1.0  < 0.01 8.6 1.0  < 0.01 – – –
 25–49% 22 8280 1.9 (0.6–6.7) 0.29 4.0 (1.7–9.8)  < 0.01 – – –
 50–74% 71 28,935 4.5 (1.5–14.0)  < 0.01 7.8 (3.3–18.2)  < 0.01 – – –
 75–100% 53 15,243 6.2 (2.0–19.4)  < 0.01 19.1 (7.9–46.1)  < 0.01 – – –
HSV-2 prevalencec
150 53,241 1.02 (1.01–1.04)  < 0.01  < 0.01 7.1 – – – 1.04 (1.03–1.05)  < 0.01  < 0.01
WHO region
 AMRO 41 12,037 1.0  < 0.01 34.0 1.0  < 0.01 1.0  < 0.01
 EURO 3 718 1.3 (0.3–5.6) 0.71 4.1 (1.2–14.6) 0.03 6.5 (2.0–21.2)  < 0.01
 SEARO 71 24,047 8.5 (5.3–13.6)  < 0.01 10.3 (6.3–16.9)  < 0.01 11.3 (7.1–17.8)  < 0.01
 WPRO 38 17,846 3.8 (2.2–6.6)  < 0.01 5.3 (3.0–9.5)  < 0.01 5.5 (3.2–9.4)  < 0.01
Publication year
 < 2000 10 2920 1.0 0.02 5.4 – – – – – –
 2000–2004 4 734 0.7 (0.1–3.6) 0.63 – – – – – –
 2005–2009 36 10,101 1.3 (0.4–3.5) 0.67 – – – – – –
 2010–2014 93 37,170 2.4 (0.9–6.2) 0.08 – – – – – –
 2015–2019 10 3723 0.7 (0.2–2.7) 0.63 – – – – – –
Data collection yeard
 < 1995 12 3384 1.0  < 0.01 23.4 1.0  < 0.01 1.0  < 0.01
 1995–1999 12 2059 1.2 (0.4–3.4) 0.76 0.5 (0.2–1.3) 0.15 0.5 (0.2–1.2) 0.12
 2000–2004 42 11,247 0.7 (0.3–1.7) 0.44 0.8 (0.4–1.6) 0.59 0.8 (0.4–1.5) 0.42
 2005–2009 81 34,649 3.6 (1.6–8.0)  < 0.01 1.7 (0.8–3.4) 0.17 1.6 (0.8–3.0) 0.18
 2010–2014 6 3309 0.6 (0.2–2.1) 0.39 0.3 (0.1–1.0) 0.04 0.4 (0.2–1.0) 0.06
Sample size
 < 200 36 4422 1.0 0.38 0.0 – – – – – –
 ≥ 200 117 50,226 1.3 (0.7–2.3) 0.38 – – – – – –
Proportion of FSWs reporting consistent condom use
 75–100% 73 30,137 1.0  < 0.01 11.6 1.0 0.07 1.0 0.04
 50–74% 16 5537 0.3 (0.1–0.6)  < 0.01 1.6 (0.8–3.1) 0.17 1.6 (0.9–2.9) 0.14
 25–49% 19 3967 0.9 (0.4–1.8) 0.69 2.7 (1.4–5.3)  < 0.01 2.7 (1.5–5.1)  < 0.01
 < 25% 3 988 0.3 (0.1–1.5) 0.15 1.1 (0.3–3.8) 0.88 1.3 (0.4–4.2) 0.62
 Unclear 42 14,019 0.3 (0.2–0.5)  < 0.01 1.6 (0.9–2.7) 0.11 1.4 (0.9–2.4) 0.16
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 network9. Meanwhile, higher degree correlation, that is broad connectivity between sexual partnerships, appears 
to favor HSV-2 spread, but not  HIV9. This suggests that, despite the strength of the association, HSV-2 cannot 
be used as the sole predictor of HIV epidemic potential.
Our findings indicated only a small role for self-reported condom use in predicting HIV prevalence (Tables 2 
and 3), suggesting that such self-reported behavioral measures may not carry meaningful explanatory power, 
and affirming documented issues in self-reported  measures11,12,33.
Our study has limitations. There was variability in the number of paired HSV-2/HIV prevalence measures 
among FSWs across regions, thus limiting our ability to perform further stratified, region-specific, analyses. For 
instance, there was an insufficient number of studies from EURO to warrant meaningful analysis and interpreta-
tion, and no studies from EMRO. Our regional estimates may have also been biased by some countries having 
larger data contributions (that is more or larger sample size studies) than others, but meta-regression analyses did 
not identify an association with study sample size. There was also heterogeneity in HIV prevalence, as commonly 
seen in observational studies assessing  prevalence5,34. The latter, however, was (mostly) explained through the 
meta-regression analyses, which affirmed HSV-2 prevalence as an independent contributor to this heterogeneity 
(Tables 2 and 3). Only a handful of studies reported age-related data, and these varied immensely in the type of 
reported measure, thus constraining age inclusion in the analysis.
A number of studies did not report data on condom use among FSWs, and very few reported coverage for 
other interventions to warrant their inclusion in the analyses. For example, only one study reported antiretroviral 
therapy (ART) coverage (Table S1 of SI), which presumably could affect the association between HIV and HSV-2 
prevalence. This being said, most studies were conducted before the mass scale up of ART (Table 2), and thus 
ART is unlikely to have affected the observed association in the current analysis but may impact future analyses 
on future data examining this association. Few studies also reported data on current injecting drug use, a non-
sexual mode of HIV transmission, with overall no major differences across regions. The latter however is unlikely 
to have affected the observed HSV-2/HIV association given that the median fraction of FSWs currently injecting 
drugs is < 5% (Table S1 of SI). Our findings also showed that even in studies where the proportion of FSWs who 
inject drugs was ≥ 5%, HSV-2 prevalence was substantial with a median of 72%, likely given the nature of the 
study population and/or the likelihood of exchanging sex for drugs.
The association between HIV prevalence and HSV-2 prevalence is likely non-linear, although the distribu-
tion of measures (Fig. 2) and an earlier mathematical modeling  analysis8 suggested that this association may not 
be far from linearity (above the threshold effect). This implies that our AOR for the HIV/HSV-2 (linear term) 
association should be interpreted with caution as an estimate for the average increase in odds of HIV prevalence 
per 1% increase in HSV-2 prevalence beyond the 20% threshold. While HSV-2 prevalence was probably at 
endemic equilibrium given infection circulation in human populations for centuries, HIV prevalence may not 
have been at equilibrium, but we were unable to account for the HIV epidemic phase in the  analysis17. Despite 
these limitations, the parsimonious multivariable meta-regression models explained > 65% of the variation in 
HIV prevalence supporting the inferences drawn in this study.
In conclusion, we demonstrated an association between HSV-2 prevalence and HIV prevalence among FSWs 
that can be utilized in assessing HIV epidemic potential in this at-risk population. We also demonstrated the 
relevance of integrating testing for HSV-2 in HIV surveillance activities targeting this population, especially in 
settings where HIV prevalence among them is still at negligible or low level. Our findings stress the need for 
HSV-2 testing in future surveillance efforts, notably in IBBSS surveys, as a tool to inform HIV preparedness and 
resource allocation, particularly in countries where HIV epidemic potential among key populations remains 
unknown. Such data is essential to avoid the costly implications of emerging HIV epidemics and to ensure that 
countries are still “on track” towards ending  AIDS35.
Methods
Data sources and selection methods. We updated a database of paired HSV-2 and HIV prevalence 
measures, retrieved through an earlier systematic  review20, by conducting a new search focused on FSWs, on 
September 3rd, 2019, using broad MeSH/Emtree and free text terms for “sex work”, “women”, “HSV-2”, and 
“HIV” (search criteria in Box S1 of SI). Paired measures eligible for inclusion were identified through a system-
atic review process following Cochrane Collaboration  guidelines36. Briefly, PubMed, Embase, and the abstract 
archives of International AIDS Society conferences were surveyed. Citations were screened for duplication, and 
then for relevance using Endnote (Thomson Reuters, USA). Full-texts of articles deemed relevant or potentially 
relevant underwent further screening, and paired measures for HSV-2 and HIV antibody prevalence (sero-
prevalence), based on primary data, were identified and extracted along with key information on study popula-
tion characteristics, year(s) of data collection, year of publication, country of origin/survey, number tested and 
number positive for HSV-2 and HIV infections, diagnostic tests used for infections’ ascertainment, proportion 
of FSWs who inject drugs, proportion of infected FSWs on ART, and proportion of FSWs reporting consistent 
condom use. The latter was assessed primarily using self-reported condom use at last sex with client, or alterna-
tively using self-reported “consistent/regular” condom use or condom use “all the time” during commercials sex 
acts (extraction list in Box S2 of SI).
Plan of analysis. Descriptive analysis. Scatterplots were generated to illustrate the distribution of paired 
HSV-2 and HIV prevalence measures among FSWs across world regions. Countries’ regional classification was 
based on the WHO regional definition (WHO classification in Box S3 of SI)37. Maps showing countries’ data 
contribution were generated using Tableau Desktop v.10.138. Studies were classified into four categories based 
on HSV-2 prevalence level among FSWs (< 25%, 25–49%, 50–74%, and 75–100%). Descriptive statistics of the 
reported HIV prevalence measures were then calculated stratified by HSV-2 prevalence category.
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Meta‑analysis. Forest plots were used to visualise estimates of HIV prevalence and 95% CIs for each HSV-2 
stratum. The pooled mean HIV prevalence and associated 95% CIs were estimated, for different HSV-2 strata, 
using random-effects meta-analysis. Here, variances of HIV prevalence measures were first stabilized using a 
Freeman-Tukey type arcsine square-root  transformation39,40. Prevalence measures were then weighted using the 
inverse-variance  method40,41, and subsequently pooled using a DerSimonian-Laird random-effects  model42 to 
account for sampling variation and true between-study  heterogeneity43.
Heterogeneity across HIV prevalence measures was assessed, with and without considering HSV-2 stratifica-
tion, using: Cochran’s Q statistic to confirm existence of heterogeneity across prevalence measures,  I2 to quantify 
magnitude of variation that is due to true differences in prevalence across studies rather than chance, and predic-
tion interval to estimate the 95% interval of the distribution of true prevalence  measures43,44. Additional meta-
analyses contrasting the African Region to the rest of world regions were performed, for relevance, as almost 
all HSV-2 prevalence measures in this region were > 50% (in contrast to the other regions), and considering the 
unique HIV epidemic history in this part of the  world1.
Meta-analyses were implemented in R v.3.4.245.
Meta‑regression. Random-effects meta-regression analyses were conducted to assess whether HSV-2 preva-
lence can be used as a predictor of HIV prevalence among FSWs. Covariates, considered a priori, included: WHO 
region (AMRO, AFRO, EMRO, EURO, SEARO, and WPRO), publication year (< 2000, 2000–2004, 2005–2009, 
2010–2014, 2015–2019), data collection year (< 1995, 1995–1996, 2000–2004, 2005–2009, 2010–2014), study 
sample size (< 200, ≥ 200), and proportion of FSWs reporting consistent condom use (< 25%, 25–49%, 50–74%, 
75–100%, unclear). Proportion of FSWs who inject drugs could not be factored in our analysis given the low 
number of studies and heterogeneity across measures (Table S1 of SI). The proportion of infected FSWs on ART 
also could not be factored in our analysis as only a single measure was identified (Table S1 of SI). Missing values 
for year of data collection were imputed using data for year of publication adjusted by the median difference 
between year of publication and year of data collection (for studies with complete information). Meta-regression 
analyses were performed using two scenarios including and excluding AFRO. Meta-regressions estimated the 
odds ratios of HIV infection assuming that the probability of HIV infection for a given population is equal to that 
of HIV prevalence in this population.
Factors associated with HIV prevalence at p value ≤ 0.20 in univariable analysis were eligible for inclusion 
in the multivariable analysis. Two multivariable models were considered using HSV-2 prevalence as a categori-
cal variable, or as a linear term after excluding HSV-2 prevalence ≤ 20% given observed threshold effect. In the 
multivariable model, a p value of ≤ 0.05 for any factor indicated strong evidence for an association with HIV 
prevalence, while 0.05 < p value ≤ 0.1 indicated some evidence for an association with prevalence.
Meta-regressions were implemented in Stata/SE v.1646.
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